Get our Free Patent Expiration Newsletter

Serving hundreds of leading biopharmaceutical companies globally:

Julphar
UBS
Boehringer Ingelheim
Chubb
Moodys
Accenture

Generated: August 18, 2019

DrugPatentWatch Database Preview

Claims for Patent: 8,559,007

  Try a free trial


See Plans and Pricing

« Back to Dashboard

Summary for Patent: 8,559,007
Title:Systems for measuring properties of a physiological fluid suspension
Abstract: A method of evaluating a property of a physiological fluid suspension comprises measuring a value of the property of a liquid portion of the physiological fluid suspension via light scattering, and comparing the measured value with a reference value to evaluate the property of the liquid portion of the physiological fluid suspension.
Inventor(s): Sukavaneshvar; Sivaprasad (Murray, UT), Teitel; Edward R. (Houston, TX), Mohammad; Syed F. (Salt Lake City, UT)
Assignee: Aggredyne, Inc. (Houston, TX)
Application Number:13/547,729
Patent Claims:1. A method of evaluating the ability of a fluid to clot, comprising: inducing flow of a fluid within a fluid container by exerting force on the fluid; measuring a baseline flow rate of the fluid before inducing clotting; inducing clotting within the fluid; measuring a secondary flow of the fluid during or after inducing clotting and while the fluid is acted upon by the force; and determining a degree of clotting in the fluid based on a difference between the baseline flow rate and the secondary flow rate of the fluid.

2. The method of claim 1, wherein the fluid is selected from the group consisting of whole blood, platelet suspensions, leukocyte suspensions, red blood cell suspensions, plasmas, and combinations thereof.

3. The method of claim 2, wherein the fluid is blood or plasma, and the method further comprises inducing platelet aggregation in the blood or plasma prior to measuring the baseline flow rate of the blood or plasma.

4. The method of claim 3, wherein measuring the baseline flow rate of the blood or plasma, and measuring the secondary flow rate of the blood or plasma, includes utilizing platelet aggregates as optical markers.

5. The method of claim 1, further comprising mixing the fluid after inducing clotting in the fluid and prior to measuring the secondary flow rate of the fluid.

6. The method of claim 1, wherein measuring the baseline flow rate and measuring the secondary flow rate includes utilization of an optical fluid flow measurement system.

7. The method of claim 1, wherein measuring the baseline flow rate and measuring the secondary flow rate includes utilization of a light scattering measurement system.

8. The method of claim 1, wherein inducing clotting within the fluid comprises adding a clotting agent to the fluid.

9. The method of claim 8, wherein the clotting agent is introduced into the container prior to introducing the fluid into the container.

10. The method of claim 8, wherein the clotting agent is selected from the group consisting of calcium salts, thromboplastin, actin, thrombin, silica, diatomaceous earth, kaolin, russel viper venom, ristocetin, clotting factors, and mixtures or combinations thereof.

11. The method of claim 1, wherein inducing flow of the fluid, measuring the baseline flow rate and the secondary flow rate, and determining the degree of clotting in the fluid are automated processes performed by an integral testing system.

12. The method of claim 1, wherein the flow is induced by at least one of: a rotor, stir bar, plunger, roller pump, vacuum, or pneumatic drive.

13. The method of claim 12, wherein the flow is induced by a rotor.

14. The method of claim 1, wherein inducing flow of the fluid does not detrimentally alter properties of the fluid.

15. The method of claim 1, wherein the flow of the fluid is recirculated flow.

16. A system for determining a degree of clotting within a fluid, comprising: a container for retaining a fluid therein; a flow inducing system operable to induce flow of the fluid retained within the container both before and after the fluid undergoes clotting; a clot inducing system, operable to induce clotting in the fluid retained within the container; and a fluid flow measurement system operable to measure at least a baseline fluid flow rate before inducing clotting of the fluid retained in the container, and a secondary flow rate during or after inducing clotting of the fluid retained in the container; wherein a degree of clotting of the fluid is determined by comparing the baseline flow rate of the fluid and the secondary flow rate of the fluid.

17. The system of claim 16, wherein the fluid is present in the container and is selected from the group consisting of whole blood, platelet suspension, leukocyte suspension, red blood cell suspension, plasma, and mixtures thereof.

18. The system of claim 16, wherein the fluid flow measurement system is an optical fluid flow measurement system.

19. The system of claim 16, wherein the fluid flow measurement system is a light scattering measurement system.

20. The system of claim 16, wherein the clot inducing system includes an opening providing selective communication between an internal environment of the container and an environment external to the container, to allow an operator to selectively introduce a clotting agent into the container.

21. The system of claim 16, further comprising a comparator, operable to receive information from the fluid flow measurement system to determine the degree of clotting of the fluid, or a rate of change of clotting of the fluid.

22. The system of claim 16, wherein the flow inducing system includes at least one of: a rotor, stir bar, plunger, roller pump, vacuum or pneumatic drive.

23. The system of claim 16, wherein the flow inducing system includes a rotor.

24. The system of claim 16, further comprising a disruption member operable to induce or enhance mixing of the fluid within the container.

25. A method of evaluating the ability of a fluid suspension to clot, comprising: inducing flow of a fluid suspension within a fluid container by exerting force on the fluid; measuring a baseline flow rate of the fluid suspension before inducing clotting; inducing clotting within the fluid suspension; measuring a secondary flow of the fluid suspension during or after inducing clotting and while the fluid suspension is acted upon by the force; determining a rate of change of flow rate of the fluid suspension based on the baseline flow rate and the secondary flow rate of the fluids; and determining a degree of clotting in the fluid suspension based on the rate of change of flow rate of the fluid suspension.

26. The method of claim 25, wherein the fluid suspension includes an anticoagulant.

27. The method of claim 26, wherein the anticoagulant is introduced into the fluid suspension prior to, along with, or after the clotting agent.

28. The method of claim 26, wherein the anticoagulant is selected from the group consisting of unfractionated heparin, low molecular weight heparin, hirudin, direct thrombin inhibitors, Factor Xa inhibitors, sodium citrate, ethylene di-amine tetra acetic acid (EDTA), antithrombin III, and combinations thereof.

29. The method of claim 25, wherein the fluid includes a thrombolytic agent.

30. The method of claim 29, wherein the thrombolytic agent is introduced into the fluid suspension prior to, along with, or after the clotting agent.

31. The method of claim 29, wherein the thrombolytic agent is selected from the group consisting of tissue plasminogen activator (tPA), streptokinase, urokinase, plasmin, serine endopeptidases, and combinations thereof.

32. The method of claim 25, wherein the fluid suspension includes a platelet aggregating agent.

33. The method of claim 32, wherein the platelet aggregating agent is introduced into the fluid suspension prior to, along with, or after an antiplatelet agent.

34. The method of claim 32, wherein the platelet aggregating agent is selected from the group consisting of adenosine di-phosphate, thrombin receptor agonist peptide, arachidonic acid, epinephrine, collagen, ristocetin, calcium ionophone, platelet factor 4, thrombin, thromboxane, and vasodilator-stimulated phosphoprotein.

35. The method of claim 33, wherein the antiplatelet agent is selected from the group consisting of aspirin, thienopyridines and its metabolites, glycoprotein inhibitors (abciximab, tirofiban, eptifibatide), and dipyridamole.

Details for Patent 8,559,007

Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Estimated Patent Expiration Status Orphan Source
Centocor Inc REOPRO abciximab INJECTABLE; INJECTION 103575 001 1994-12-22 ➤ Sign Up Aggredyne, Inc. (Houston, TX) 2028-03-05 RX search
Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Estimated Patent Expiration Status Orphan Source

Subscribe to access the full database, or try a Free Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving hundreds of leading biopharmaceutical companies globally:

UBS
Merck
Deloitte
Fish and Richardson
AstraZeneca
Argus Health

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.